05:09 PM EST, 11/12/2024 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) reported a Q3 net loss late Tuesday of $0.96 per diluted share, narrowing from a loss of $1.01 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.91.

No revenue was recorded for the quarter that ended Sept. 30, compared with $346,000 a year earlier. Analysts surveyed by Capital IQ projected $0.2 million.

The company said its cash, cash equivalents, and investment securities will be sufficient to fund its current operating plan into 2029.

Price: 60.00, Change: +1.14, Percent Change: +1.94